Utuly intranasal epinephrine developer Bryn Pharma has named Sandy Loreaux as CEO, succeeding David Dworaczyk, who will remain with the company as head of R&D, regulatory, and production. Loreaux was most recently US President of Covis Pharma and previously held executive positions at Mallinckrodt, Valeant, and Sanofi-Aventis.
Bryn recently announced results of a bioeavailability study demonstrating that a 13.2 mg dose of Utuly nasal spray absorbed as fast as EpiPen epinephrine autoinjector and produced higher and longer-lasting levels of epinephrine. Utuly is delivered via Aptar Pharma’s Bidose nasal device.
Bryn Pharma Chairman of the Board Steven Hartman commented, “Over the past 5-plus years, we’ve been a development-stage company focusing on Utuly’s NDA submission and approval. David’s efforts have brought us from an idea of building a non-needle, easy to use, easy to carry emergency epinephrine delivery device to being on the cusp of filing our NDA. We appreciate David’s dedication, development expertise, scientific acumen and continued insights as he leads the completion and filing of Utuly’s NDA submission. Now we must evolve into a commercial-stage company. Sandy’s extensive pharmaceutical commercialization and leadership experience will be instrumental to Bryn as we advance Utuly. While Sandy has already made significant contributions to Bryn as a member of our board of directors, her day-to-day involvement comes at a critical time to guide us through a successful launch.”
Read the Bryn Pharma press release.
